# OnCo record stage-iii-melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/stage-iii-melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "stage-iii-melanoma" ;
  schema:name "Stage III melanoma (after surgery)"@en ;
  schema:alternateName "Resected stage III melanoma"@en, "Node-positive melanoma"@en, "Regional melanoma"@en, "Adjuvant melanoma setting"@en ;
  schema:description "Stage III melanoma has spread to nearby lymph nodes but not further, and after surgery a year of immunotherapy, or of targeted pills if the cancer has a BRAF mutation, roughly halves the chance of it coming back. The newest trials show that giving immunotherapy before the operation instead of after works even better and lets most people stop treatment early."@en ;
  schema:url <https://onco.cc/cancers/stage-iii-melanoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Melanoma> ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJMoa1709030>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1802357>, <https://www.nejm.org/doi/full/10.1056/NEJMoa2402604>, <https://en.wikipedia.org/wiki/Melanoma> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/intismeran-autogene/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/terms/breslow-thickness/>, <https://onco.cc/terms/ulceration-melanoma/>, <https://onco.cc/terms/efs/> ;
  onco:trials <https://onco.cc/trials/checkmate-238/>, <https://onco.cc/trials/nct02362594/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/trials/swog-s1801/>, <https://onco.cc/trials/nadina/>, <https://onco.cc/trials/interpath-001/>, <https://onco.cc/trials/mslt-ii/> ;
  onco:people <https://onco.cc/people/alexander-eggermont/>, <https://onco.cc/people/jeffrey-weber/>, <https://onco.cc/people/christian-blank/>, <https://onco.cc/people/georgina-long/>, <https://onco.cc/people/sapna-patel/> ;
  onco:pipeline <https://onco.cc/trials/interpath-001/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/ideas/idea-ctdna-guided-adjuvant-melanoma/>, <https://onco.cc/trials/nct04079166/>, <https://onco.cc/trials/nct05280314/>, <https://onco.cc/trials/relativity-098/> ;
  onco:standardOfCare <https://onco.cc/trials/mslt-ii/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/trials/nadina/>, <https://onco.cc/trials/swog-s1801/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/major-pathological-response/>, <https://onco.cc/trials/checkmate-238/>, <https://onco.cc/trials/nct02362594/>, <https://onco.cc/trials/combi-ad/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/trials/interpath-001/>, <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/drugs/talimogene-laherparepvec/>, <https://onco.cc/trials/nct02938299/>, <https://onco.cc/trials/nct03567889/>, <https://onco.cc/technologies/isolated-limb-perfusion/>, <https://onco.cc/technologies/electrochemotherapy/> .